Screener examples › Australia
Australian stocks near 52-week highs
Growing companies breaking out in Australia.
“Stocks listed in Australia within 3% of their 52-week high with revenue growth above 10% and market cap over $1B”
Run this screen live and refine it in plain English (free, no sign-up).
Australia-listed operating companies within 3% of their 52-week high, growing revenue over 10% with market cap above $1B.
Filters: Within 3% of 52-week high; Revenue growth > 10%; Market cap > $1B; Listed in Australia
Top matches on data as of October 26, 2026
| Symbol | Company | Exchange | Sector | Industry | Price | Currency | From 52W High | 52W High | Rev Growth YoY |
|---|---|---|---|---|---|---|---|---|---|
| IAG | Insurance Australia Group Limited | ASX | Financials | Insurance - Property & Casualty | $8.89 | AUD | -0.3% | $8.92 | 46.6% |
| ANN | Ansell Limited | ASX | Healthcare | Medical - Instruments & Supplies | $46.50 | AUD | -0.6% | $46.77 | 27.7% |
| CWY | Cleanaway Waste Management Limited | ASX | Industrials | Waste Management | $2.99 | AUD | -0.7% | $3.01 | 12.6% |
| SDF | Steadfast Group Limited | ASX | Financials | Insurance - Brokers | $5.81 | AUD | -0.7% | $5.85 | 25.2% |
| ASX | ASX Limited | ASX | Financials | Financial - Data & Stock Exchanges | $65.59 | AUD | -0.7% | $66.06 | 15.3% |
| QBE | QBE Insurance Group Limited | ASX | Financials | Insurance - Property & Casualty | $26.18 | AUD | -1.5% | $26.58 | 10.4% |
| AN3PI | ANZ Group Holdings Ltd | ASX | Financials | Banks - Diversified | $102.56 | AUD | -1.7% | $104.35 | 28.1% |
| RHC | Ramsay Health Care Limited | ASX | Healthcare | Medical - Care Facilities | $54.94 | AUD | -1.9% | $55.98 | 14.9% |
| CSL | CSL Limited | ASX | Healthcare | Biotechnology | $195.14 | AUD | -1.9% | $198.92 | 26.4% |
| ANZ | ANZ Group Holdings Limited | ASX | Financials | Banks - Diversified | $39.90 | AUD | -2.7% | $41.00 | 28.1% |
| AN3PL | Australia and New Zealand Banking Group Ltd | ASX | Financials | Banks | $105.42 | AUD | -2.8% | $108.48 | 106.6% |
11 matches. Research data, not investment advice.